Results 121 to 130 of about 14,134,939 (334)

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

open access: yesMolecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke   +12 more
wiley   +1 more source

Teaching Literature Reviewing for Software Engineering Research [PDF]

open access: yesarXiv
The goal of this chapter is to support teachers in holistically introducing graduate students to literature reviews, with a particular focus on secondary research. It provides an overview of the overall literature review process and the different types of literature review before diving into guidelines for selecting and conducting different types of ...
arxiv  

The Adventures of Ralph Rashleight A Penal Exile in Australia, 1825-1844 [PDF]

open access: yes, 1929
https://commons.und.edu/settler-literature/1110/thumbnail ...
Tucker, James
core   +1 more source

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

open access: yesMolecular Oncology, EarlyView.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina   +17 more
wiley   +1 more source

Jock of the Bushveld [PDF]

open access: yes, 1907
https://commons.und.edu/settler-literature/1194/thumbnail ...
Fitzpatrick, James Percy
core   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale   +9 more
wiley   +1 more source

Scanning the Literature [PDF]

open access: yesIEEE Wireless Communications, 2011
Provides an overview of the technical articles and features of interest to readers that appear outside of this publication.
openaire   +2 more sources

A Bibliography of Canadian Fiction [PDF]

open access: yes, 1904
https://commons.und.edu/settler-literature/1116/thumbnail ...
Burpee, Lawrence J.   +1 more
core   +1 more source

The accumulation of myeloid‐derived suppressor cells participates in abdominal infection‐induced tumor progression through the PD‐L1/PD‐1 axis

open access: yesMolecular Oncology, EarlyView.
This study explores how sepsis affects GC progression by creating an immunosuppressive environment. Our findings reveal that sepsis promotes immune dysregulation, enhancing tumor growth and metastasis. Targeting the PD‐1/PD‐L1 pathway with monoclonal antibodies shows potential for restoring immune function and improving outcomes in cancer patients ...
Yiding Wang   +10 more
wiley   +1 more source

The PTTG1/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments

open access: yesMolecular Oncology, EarlyView.
VASP was found to be overexpressed in metastatic oral squamous cell carcinoma (OSCC) tissues. Notably, PTTG1‐ and VASP‐deficient OSCC cells demonstrated suppressed metastatic properties by disrupting the interaction between the cytoskeleton and focal adhesion (FAs) in the filopodia region.
Suyeon Park   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy